This meta-analysis pools data from 7 randomized trials to estimate the association between administration of corticosteroids vs usual care or placebo and all-ca
A Preclinical Trial Demonstrates the Benefits of Inhaled Pherecydes Pharma Phages in Treating Ventilation-Associated Pneumonia
th Annual Inhalation and Respiratory Drug Delivery Congress (April 20-21, 2021)
Regulatory News:
Pherecydes Pharma (FR0011651694 ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that Nathalie Heuzé-Vourc h of the
Centre d Etude des Pathologies Respiratoires (Research Center for Respiratory Diseases) (UMR INSERM-Université de Tours U1100) will present the results of a preclinical study undertaken with the phages of Pherecydes Pharma at the
6
The presentation, entitled
Inhaled phage therapy to treat Ventilation Associated Pneumonia